Eclipsys/Allscripts Merger
On June 9, 2010 Allscripts (Nasdaq: MDRX) and Eclipsys (Nasdaq: ECLP) announced a definitive agreement to merge in an all-stock transaction valued at approximately $1.3 billion.
Under terms of the merger agreement, Eclipsys stockholders will receive 1.2 shares of Allscripts for each share of Eclipsys, a 19 percent premium based on the June 8th closing price.
UBS, Barclays Capital and J.P. Morgan acted as financial advisors to Allscripts on the merger, and Blackstone and William Blair acted as financial advisors to the Audit Committee of Allscripts. Perella Weinberg Partners acted as financial advisor to Eclipsys. Credit Suisse acted as financial advisor to Misys.
The companies expect the merger to close in approximately four to six months.
-
QlikTech (QLIK) Names Tim MacCarrick as CFO
-
Allscripts (MDRX) Higher as First-Round Bidding Complete
-
UPDATE: Piper Says 'Challenges' Lowers Allscripts (MDRX) Takeover Value, Sees Bids at $14/Share
-
Auriga Upgrades Allscripts-Misys Healthcare (MDRX) to Buy; All Aboard Allscripts (Again!)
-
FBR Capital Maintains a 'Market Perform' on Allscripts-Misys Healthcare (MDRX); 1Q11 Shows Solid Results While Bookings Pullback Does Raise Some Concern
-
Auriga Downgrades Allscripts-Misys Healthcare (MDRX) to Hold
-
FBR Capital Starts Allscripts-Misys Healthcare (MDRX) at Market Perform; Merged Healthcare IT Co. Has Strong Base, But Plenty of Work to Do
-
Barclays Maintains an 'Overweight' on Allscripts-Misys Healthcare (MDRX); Bookings Boost Highlights Q4, with Our 2011 Estimates Again Up-Ticked
-
Barclays Maintains an 'Overweight' on Allscripts-Misys Healthcare (MDRX); Tone Into 4Q: Focus on Eclipsys Growth, Progress on Merger Integration
-
UBS Reiterates a 'Buy' Allscripts-Misys Healthcare (MDRX); Refreshing HIT Company Valuations
-
Deutsche Bank Upgrades Allscripts-Misys Healthcare (MDRX) to Buy
-
Barclays Reinstates an 'Overweight' Rating on Allscripts Healthcare (MDRX); Just What the Doctor Could Order
-
Auriga Maintains a 'Buy' Rating on Allscripts-Misys (MDRX); Updating Model to Reflect Eclipsys, Fiscal Year Change
-
Deutsche Bank Reinstates Allscripts (MDRX) with a 'Hold'; ECLP Transaction May Yield Upside, But Valuation & Risks Balanced

